CDK4/6 inhibitors are standard of care in the treatment of metastatic breast cancer. Treatment regimen consists of a combination with endocrine therapy, since their therapeutic efficacy as monotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results